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Article focus
  a synthesis of the current knowledge on 
the pathways leading to the develop-
ment of Charcot neuroarthropathy in dia-
betic neuropathy.
Key messages
  Charcot neuroarthropathy develops 
due to an interplay of several mecha-
nisms including, abnormalities of bone 
formation and resorption, upregulation 
of pre-inflammatory mediators and non-
enzymatic glycosylation of tissue.
Strengths and limitations
  a up-to-date summary of the state of 
knowledge regarding the pathogenesis 
of Charcot neuroarthropathy.
  a final common pathway for the devel-
opment of Charcot neuroarthropathy 
remains elusive.
Introduction
Charcot neuroarthropathy (CNa) is a rare but 
serious complication of peripheral neuropa-
thy, with fracture and dislocation of the 
bones and joints of the foot leading to 
deformity, altered biomechanics and an 
increased risk of ulceration if left untreated. 
Diabetes mellitus is the most common cause 
of neuropathy and consequently of CNa in 
the developed world. The prevalence of CNa 
is disputed, but is likely to affect between 1% 
and 2% of patients with diabetic neuropa-
thy.1,2 The underlying mechanisms were ini-
tially thought to be repeated trauma to the 
insensate foot (neurotraumatic) combined 
with dysregulation of the vasomotor and 
trophic nerve supply (neurovascular).
management is complicated by a lack of 
consensus on the diagnostic criteria and an 
incomplete understanding of the pathogen-
esis. more recent work has provided an 
neuroarthropathy in diabetes: 
pathogenesis of charcot arthropathy
charcot neuroarthropathy is a rare but serious complication of diabetes, causing progres-
sive destruction of the bones and joints of the foot leading to deformity, altered biomechan-
ics and an increased risk of ulceration.
Management is complicated by a lack of consensus on diagnostic criteria and an incom-
plete understanding of the pathogenesis. In this review, we consider recent insights into the 
development of charcot neuroarthropathy.
It is likely to be dependent on several interrelated factors which may include a genetic 
pre-disposition in combination with diabetic neuropathy. This leads to decreased neuro-
peptides (nitric oxide and calcitonin gene-related peptide), which may affect the normal 
coupling of bone formation and resorption, and increased levels of Receptor activator of 
nuclear factor kappa-B ligand, potentiating osteoclastogenesis.
Repetitive unrecognized trauma due to neuropathy increases levels of pro-inflammatory 
cytokines (interleukin-1β, interleukin-6, tumour necrosis factor α) which could also con-
tribute to increased bone resorption, in combination with a pre-inflammatory state, with 
increased autoimmune reactivity and a profile of monocytes primed to transform into osteo-
clasts - cluster of differentiation 14 (cD14).
Increased blood glucose and loss of circulating Receptor for Advanced Glycation end-
products (AGLeps), leading to increased non-enzymatic glycation of collagen and accumu-
lation of AGLeps in the tissues of the foot, may also contribute to the pathological process.
An understanding of the relative contributions of each of these mechanisms and a final 
common pathway for the development of charcot neuroarthropathy are still lacking.
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insight into the role of inflammation and abnormal bone 
in the pathogenesis of CNa. However, most studies are 
small and document the markers of bone turnover and 
inflammation without conclusive evidence of causation.3 
Few studies include histology of the bone and soft tissues 
of the feet in patients with CNa. la Fontaine et al4 investi-
gated the quality of bone in seven normal subjects, eight 
patients with diabetes and five with active and five with 
chronic CNa. In the samples from those with diabetes 
they identified thinner trabeculae, reduced cellularity and 
thickened tunica media of the vessels in the marrow 
spaces. The samples from those with CNa had more 
Howship’s lacunae, more woven bone and an inflamma-
tory infiltrate of lymphocytes and eosinophils in the mar-
row spaces, suggesting that inflammation and reduced 
bone density are both involved in its pathogenesis.
an understanding of the relative contributions of genetic 
susceptibility, inflammation, altered neurotrophic factors 
and disordered bone turnover and a final common path-
way for the development of CNa are still lacking. In this 
paper we review the literature relating to the pathogenesis 
of CNa at a molecular level.
Search strategy. The search terms ‘Charcot foot’ and 
‘neuroarthropathy’ were applied to EmBaSE (1974 to the 
present) and mEDlINE (1946 to the present), produc-
ing 895 articles. Removal of duplicates resulted in 809 
and review of titles for relevance to pathogenesis left 66 
articles. Further exclusions were made after review of 
the abstracts, leaving 45 articles to be reviewed in full. a 
further eight were then identified from the references of 
these papers.
Inflammation and the balance of pro-/anti-inflammatory 
cytokines. In 2016, molligan et al5 published a small study 
of the role of the synovium and fibroblast-like synovio-
cytes in the development of Charcot neuroarthropathy. 
Synovial samples were taken from seven feet of non-
diabetic control patients undergoing surgery for correc-
tion of a deformity or osteoarthritis and seven with CNa, 
although whether it was active or inactive was not stated. 
They demonstrated a normal single-layer synovium in the 
controls, compared with an inflammatory multi-layered 
synovium with increased vascularity and a lymphocytic 
infiltrate in the patients with CNa. There was an increased 
propensity of the synovium to invasive behaviour after the 
addition of Tumour Necrosis Factor α (TNFα) to the cul-
ture, as is found with the synovium in rheumatoid arthritis. 
They also saw a significant increase in  cadherin-11 expres-
sion in the CNa synovium. Cadherin-11 is a cell membrane 
glycoprotein involved in signaling and previously found 
to be fundamental to the formation of pannus in rheuma-
toid synovium.6 Expression of interleukin-6 (Il6), recep-
tor activator of nuclear factor kappa-B ligand (RaNKl), a 
Disintegrin and metalloproteinase with Thrombospondin 
motifs-4 and -5 (aDamTS4 and aDamTS5) were all mark-
edly increased in patients with CNa.5 The aDamTS family 
are metalloproteases, which are important in remodelling 
the extracellular matrix; they are also implicated in the 
development of osteoarthritis.7
Increase in the pro-inflammatory cytokines, TNFα, 
Il1β and Il6, which promote local inflammation and the 
maturation and proliferation of osteoclasts via the RaNKl 
pathway, have been documented in CNa.8,9 The abnor-
mal persistence of the inflammatory response and the 
inability to terminate the response have been suggested 
as causative factors in the pathogenesis of CNa.10 a recent 
study11 using peripheral venous blood samples from ten 
patients with CNa, eight with diabetes and eight con-
trols, showed that monocytes from those with CNa spon-
taneously produced TNFα, Il1β and Il6, whereas the 
control patients, with and without diabetes, did not. Ex 
vivo stimulation of cultured monocytes with lipopolysac-
charide also significantly increased the release of TNFα, 
Il1β and Il6 compared with controls and those with dia-
betes, although significantly lower levels of the anti-
inflammatory cytokines Il4 and Il10 were released, 
indicating that the monocytes of patients with CNa are 
primed for a more intense inflammatory reaction.12 The 
monocytes from the patients with CNa also demon-
strated increased resistance to serum withdrawal-induced 
apoptosis compared with controls. This shows a decreased 
ability to terminate the inflammatory response, as well as 
increased intensity of expression of the markers CD40, 
CD80 and CD86, which are involved in antigen presenta-
tion to T-cells and therefore the activation of the RaNKl 
pathway.9
Petrova et  al13 linked markers of inflammation with 
bone turnover in a study of 81 patients, 35 with CNa, 34 
with diabetes but without neuropathy and 12 normal 
controls. Significant differences in C-reactive protein 
(CRP), TNFα and Il6 were seen between the patients with 
CNa and the diabetic and control groups. TNFα and Il6 
were also found to significantly decrease between pres-
entation and follow-up at three months in those with 
CNa. levels of c-terminal telopeptide of collagen and 
osteoprotegerin were significantly increased in those 
with CNa and positively correlated with TNFα and Il6 at 
the time of presentation, linking levels of inflammatory 
cytokines with the degree of bone resorption in CNa.
Increased extracellular vesicles have been found in the 
peripheral blood of patients with acute CNa compared 
with controls. Extracellular vesicles are membrane-bound 
nanostructures, which may be involved in communica-
tion between cells that can transport contents protected 
from the extracellular matrix. They have been identified 
at increased levels in cardiovascular and autoimmune dis-
eases and those shed from osteoblasts have been found 
to contain RaNKl. Schara et  al14 have shown levels of 
extracellular vesicles in CNa to be associated with CRP 
and increased temperature of the foot and have sug-
gested therefore that they may be useful in monitoring 
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clinical progression. However, the contents of these vesi-
cles are not known and the mechanisms by which they 
are associated with the development and progression of 
CNa have not been studied.
although it is clear that inflammation is a key compo-
nent in the development and persistence of CNa, it is not 
clear what the initiating event of the cascade is, or how 
the predisposition to a pro-inflammatory phenotype in 
diabetes interacts with abnormal bone turnover to pro-
duce the bony and soft-tissue changes.
RANKL pathway and bone turnover. low bone mineral 
density is recognized as a feature of diabetes, particu-
larly type I.15,16 This is exaggerated in CNa, with disor-
dered bone turnover mediated via the RaNKl-NFκB 
pathway.17,18 Bone turnover in CNa was investigated 
by gough et al (1997),19 using pyrodinoline-crosslinked 
carboxy-terminal telopeptide domain of type-I colla-
gen (ICTP) as a marker of bone resorption and carboxy- 
terminal propeptide of type-I collagen (PICP) and alkaline 
phosphatase as markers of bone formation.20 Peripheral 
venous and dorsal foot venous blood samples were col-
lected from 16 patients with acute CNa, 16 with chronic 
CNa, ten with diabetes and ten controls. a significant 
increase in ICTP was found in acute versus chronic CNa 
with a significant correlation between local and systemic 
levels (r = 0.986). No difference was found in the levels of 
alkaline phosphatase or PICP, suggesting that the pathol-
ogy of acute CNa is an up-regulation of bone resorption 
rather than a suppression of bone formation. a small 
study comparing 23 patients with a fracture pattern of 
CNa with a 23 who had a dislocation pattern of CNa, 
found an association with decreased peripheral bone 
mineral density only in those with the fracture pattern.21 
This introduces the possibility that the type of deformity 
that develops depends on the pre-existing bone density.
RaNKl has been found to be upregulated by several 
pathological processes in diabetes.22 Increased ambient 
glucose has been shown to induce activation of NFκB in a 
porcine vascular smooth muscle cell model.23 oxidative 
stress, caused by the addition of peroxide to culture, 
induced NFκB signaling in an in vitro rat cell culture 
model.24 The presence of advanced glycation End-
products in a bovine endothelial cell model induced 
NFκB but the effect was reversed by the addition of anti-
oxidants to the culture.25 RaNKl levels were shown to be 
increased in the serum of 12 patients with CNa compared 
with 10 patients with diabetes and five controls, and 
immunohistochemistry demonstrated upregulation in 
areas of the tibial artery affected by medial calcification in 
those with CNa.26 NFκB was shown to be inhibited by 
physiological levels of insulin added to human aortic 
endothelial cells in culture.27
a small study by Bergamini et al28 in 2016 provided 
potentially conflicting data by demonstrating signifi-
cantly decreased levels of RaNKl in circulating peripheral 
blood monocytes from patients with acute CNa com-
pared with controls. They found that increased levels of 
circulating RaNKl coincided with clinical resolution and 
suggested that there is a local compensatory mechanism 
in acute CNa which limits bone remodelling. most other 
studies have included patients with more chronic disease, 
which may have provided a different profile of RaNKl 
expression.
The Wnt/β-catenin signaling pathway is involved in 
both bone and vascular metabolism and has also been 
shown to be disrupted in diabetes, with serum levels of 
sclerostin and Dickkopf-1 found to be significantly higher 
in post-menopausal women with type-2 diabetes (n = 40) 
than in gender and age-matched controls (n = 40).29
Cluster of Differentiation 14 (CD 14) -positive cells 
have the greatest propensity of the monocytes for trans-
formation into osteoclasts.30 mabilleau et  al31 investi-
gated the proportion of circulating CD14-positive cells in 
11 patients with CNa, ten with diabetes and six controls. 
They found a 1.7-fold increase in the percentage of CD 
14-positive cells in patients with CNa compared with 
those with diabetes and a 2.1-fold increase compared 
with controls. They also identified a 1.7-fold increase in 
the pro-inflammatory cytokine TNFα in patients with 
CNa compared with those with diabetes and a 2.2-fold 
increase compared with controls, with a strong correla-
tion between TNFα levels and the proportion of CD 
14-positive cells. These findings suggest that the increased 
bone resorption seen in CNa may be related to systemic 
priming with osteoclast precursors and increased circu-
lating pro-inflammatory cytokines, and that the RaNKl 
pathway may not be the only mechanism involved.32
a number of interlinked processes appear to be 
responsible for the altered bone turnover seen in diabetic 
patients, including disruption of the Wnt/β-catenin path-
way, increased circulating osteoclast precursors and 
upregulation of the RaNK/RaNKl pathway. The underly-
ing mechanisms have not been fully elucidated but are 
postulated to include modulation by raised circulating 
glucose and increased oxidative stress.
Neuropeptides (Calcitonin Gene-Related Peptide (CGRP) 
and nitric oxide (NO)). The neuropeptides CgRP and 
substance P are released in a non-synaptic manner from 
small unmyelinated c-type nerve fibres and small myelin-
ated aδ fibres. These are found in high concentrations 
in the periosteum and bone marrow.33 They have been 
shown to upregulate osteoblastic genes and down-
regulate osteoclastic gene expressions such as Tartrate-
Resistant acid Phosphatase (TRaP), cathepsin K and NFκB 
in a mouse bone stromal cell model,34 with depletion 
in a rat model resulting in reduced bone density35 and 
the absence of CgRP in a knockout mouse model pro-
ducing an osteopenic phenotype.36 Endothelial No 
synthase (eNoS) acts via the second messenger No to 
regulate osteoclast proliferation37 and is itself regulated 
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by CgRP.38 la Fontaine et al39 investigated the levels and 
distribution of CgRP and No in samples of bone from the 
feet of four diabetic patients without neuropathy, four 
diabetic patients with neuropathy and four patients with 
chronic CNa, using immunohistochemistry and quantita-
tive image analysis. They found a non-significant decrease 
in CgRP expression (as measured on image area) and 
a significant decrease in eNoS expression between the 
patients with diabetes but no neuropathy and those with 
neuropathy with and without CNa. This is an interesting 
observation but the number of samples was small.
It is likely that the levels of neuropeptides are altered in 
the neuropathic foot and this may contribute to altered 
bone turnover but there is currently insufficient evidence 
for causation.
Hyperglycaemia and Advanced Glycation End-Products 
(AGEs)
Receptor for AGEs (RAGE) defence. agEs are proteins and 
lipids that have been modified by glycation due to the 
presence of sugars in a non-enzymatic process. Their 
formation in diabetes is a result of both hyperglycaemia 
and oxidative stress. They are found particularly in tissues 
with low turnover such as cortical bone,40 and form in 
many tissues as part of the ageing process, including in 
non-diabetics, and have also been implicated in patho-
logical processes such as atherosclerosis. agEs induce 
apoptosis in mesenchymal cells through combination 
with RagE.41 although RagE is constitutively expressed 
it may be responsible for a RaNKl-independent pathway 
for increased osteoclastogenesis and altered bone quality 
in diabetes.42 Circulating RagE is decreased in diabetes 
and provides reduced defence against the accumulation 
of agEs in tissues, which may impair the mineralization 
of bone matrix.43 a 2011 study by Witzke et  al44 of 20 
patients with non-acute CNa, 30 with diabetes and 30 
normal controls revealed seven-fold lower soluble-RagE 
values from peripheral venous blood samples in those 
with CNa than in the controls, and three-fold lower val-
ues in those with diabetes. a positive correlation was 
seen between soluble-RagE and calcaneal bone stiffness.
as CNa in the diabetic foot is a condition of weight-
bearing joints, the mechanical effect of agEs on type I 
collagen may play a role in the development of an abnor-
mal mechanical environment. Previous small molecular 
dynamics studies of collagen-like peptides have estab-
lished that non-enzymatic crosslinking to form agEs 
results in increased tensile young’s modulus and lateral 
force-displacement ratios at low strain rates compared 
with un-crosslinked collagen. This may explain the hard-
ening of tissues seen clinically.45
RagE is present on many cell types of the immune sys-
tem and is involved in the processes of both acute and 
chronic inflammation through many signaling cascades, 
particularly NFκB, activated by ligands including S100/ 
calgranulins and High mobility group Box 1. Blockade of 
RagE in a mouse model of foot injury was shown to sup-
press the inflammatory response through downregulation 
of the NFκB pathway.46 It has been suggested that in envi-
ronments of high oxidative stress such as ageing and diabe-
tes, ligands for RagE may become crosslinked, predisposing 
to a signaling cascade, which favours the perpetuation of 
chronic inflammation over rapid ligand clearance and reso-
lution of inflammation,47 although the mechanism under-
lying this remains unconfirmed and the threshold beyond 
which injury occurs has not been identified.
Autoimmunity. Rizzo et al48 studied the involvement of 
autoimmunity in order to investigate a further mecha-
nism by which agEs may potentiate inflammation in 
CNa. oxidative stress is increased in diabetes and causes 
sequential oxidative reactions, which increase levels of 
agEs and oxidative post-translational modification of tis-
sue proteins.49,50 Enzyme-linked immunosorbant assay 
(ElISa) revealed that increased binding of serum samples 
to oxidatively modified molecules, particularly type II 
collagen, was seen in patients with CNa and, to a lesser 
extent, those with diabetic neuropathy.48
Genetic factors. Previous work on susceptibility to 
osteoporosis has identified several single nucleotide 
polymorphisms (SNPs) in the gene encoding osteopro-
tegerin, a decoy receptor for RaNKl, which prevents 
binding to RaNK and activation of the NFκB path-
way, thereby preventing proliferation of osteoclasts.51 
Pitocco et al52 investigated the g1181C and T245g SNPs 
in 59 patients with CNa, 41 with diabetic neuropathy 
and 103 controls, in Italy, and established a positive cor-
relation of the g allele in both SNPs with CNa. Korzon-
Burakowska et  al53 performed similar work involving 
Polish patients. a total of 54 had CNa, 35 had diabetic 
neuropathy and there were 95 controls. They found an 
8.5-fold increased risk of CNa for the thymine-thymine 
(TT) polymorphism of the 1217 SNP and an 11.5-fold 
increase in risk for CNa with TT polymorphism of the 
245 SNP. This suggested genotypes associated with 
an underlying susceptibility to the bone homeostasis 
mechanism in some individuals. However, they could 
not demonstrate causation and these studies are small 
and likely to be underpowered.
Conclusion
The development of CNa is dependent on several inter-
related factors. Some small studies have suggested an 
underlying genetic pre-disposition and others have identi-
fied accumulation of agEs in the tissues of the foot and 
decreased neuropeptides in neuropathy (No and CgRP), 
which may affect the normal coupling of bone formation/
resorption, potentiating osteoclastogenesis. Increased 
levels of pro-inflammatory cytokines (Il1β, Il6, TNFα) and 
RaNKl have been identified, however, their temporal rela-
tionship to the development and progression of the con-
dition remains unclear.
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The relative contributions of genotype, increased pro-
inflammatory cytokines and disordered bone turnover 
and altered neuropeptide profile have yet to be deter-
mined. Few studies have included patients with active 
CNa, making it difficult to draw conclusions on causation 
and the temporal relationship of these factors with the 
development and progression of the condition. a final 
common pathway for the pathogenesis of CNa is yet to 
be determined and promising therapeutic targets have 
yet to be identified.
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